Across TCGA pan-cancer cohorts, IGHV3-16 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IGHV3-16 data layer compared with 21 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IGHV3-16 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV3-16 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD and LSCC are the cancer types where IGHV3-16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.882	1.000	.016	6	view →
LSCC	DFS	Median	All	1.000	0.421	.017	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: IGHV3-16 tumor-vs-normal RNA expression · all IGHV3-16 data types